Fonte: Virchous Archiv. Nome do evento: European Congress of Pathology. Unidade: FMRP
Assuntos: NEOPLASIAS MAMÁRIAS, BIOMARCADORES
ABNT
TIEZZI, Daniel Guimarães et al. HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin. Virchous Archiv. Heidelberg: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 03 out. 2024. , 2005APA
Tiezzi, D. G., Andrade, J. M. de, Ribeiro-Silva, A., Tiezzi, M. G., Marana, H. R. C., Zola, F. E., & Sarmento-Filho, J. M. (2005). HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin. Virchous Archiv. Heidelberg: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Tiezzi DG, Andrade JM de, Ribeiro-Silva A, Tiezzi MG, Marana HRC, Zola FE, Sarmento-Filho JM. HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin. Virchous Archiv. 2005 ; 447( 2): 364.[citado 2024 out. 03 ]Vancouver
Tiezzi DG, Andrade JM de, Ribeiro-Silva A, Tiezzi MG, Marana HRC, Zola FE, Sarmento-Filho JM. HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin. Virchous Archiv. 2005 ; 447( 2): 364.[citado 2024 out. 03 ]